Key result
Meloxicam therapy significantly improved ankle joint pathology and decreased fluorescence intensity compared to tramadol hydrochloride in rats with experimental rheumatoid arthritis.
Why the study?
Does meloxicam improve ankle joint pathology and decrease fluorescence intensity in rats with collagen-induced arthritis compared to tramadol?
Does meloxicam improve ankle joint pathology and decrease fluorescence intensity in rats with collagen-induced arthritis compared to tramadol?
Near-infrared fluorescence imaging can effectively monitor therapeutic response in a rat model of rheumatoid arthritis.
Meloxicam may outperform tramadol in rat arthritis models; leaves open translation to patients and validation of near-infrared fluorescence imaging.
An in vivo near-infrared fluorescence (NIRF) imaging technique is described for therapy monitoring of ankle joints affected by collagen-induced arthritis, a model of human rheumatoid arthritis. Arthritis was induced in rats by intradermal injections of collagen and Freund's incomplete adjuvant. For in vivo imaging, the nonspecific NIR dye tetrasulfocyanine (TSC) was used. Prior to and after treatment with a nonsteroidal anti-inflammatory drug, meloxicam, or analgesic drug, tramadol hydrochloride (which served as no-therapy control), normalized fluorescence intensities of each ankle joint were measured. Additionally, each ankle joint was characterized by clinical arthritis scoring and histopathology. Over a 3-week treatment period, a significant difference in disease progression between animals treated with meloxicam and tramadol hydrochloride was detected. A statistically significant improvement in ankle joint pathology from high- or moderate-grade to moderate- or low-grade upon meloxicam therapy, as determined by clinical evaluation, translated into a significant decrease in fluorescence intensity. In contrast, all arthritic joints of the no-therapy control group deteriorated to high-grade arthritis with high-fluorescence intensities in NIRF imaging.
No takes yet. Share an insight, caveat, or question.
Vollmer et al. (2014) studied Experimental rheumatoid arthritis. Meloxicam vs. Tramadol hydrochloride was evaluated on Disease progression (clinical arthritis scoring, histopathology, and normalized fluorescence intensities). Meloxicam therapy significantly improved ankle joint pathology and decreased fluorescence intensity compared to tramadol hydrochloride in rats with experimental rheumatoid arthritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: